Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.
Counterparty
Hebei Senlang Biotechnology Co., Ltd.
“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
Vor Biopharma Licensing Deal with RemeGen Co., Ltd. Worth $10M
Vor Biopharma expanded its existing partnership with RemeGen by entering into an amended and restated license agreement to add RC298, a next-generation dual BAFF/APRIL inhibitor, to its exclusive development and commercialization rights outside of Greater China. Vor Bio will pay an upfront cash payment of $10 million and issue a pre-funded warrant for 2.3 million shares, with RemeGen eligible for up to $630 million in development and regulatory milestones plus tiered royalties.
Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.
Edesa Biotech granted Kyorin Pharmaceutical an exclusive license to develop and commercialize its anti-TLR4 monoclonal antibody, paridiprubart (EB05), for the treatment of ARDS in Japan. Edesa receives a $12 million upfront payment and is eligible for up to $134 million in development, regulatory, and sales milestones, plus tiered double-digit royalties. Kyorin will fund all development and commercialization activities in Japan while Edesa retains rights in all other territories.
Evommune Licensing Deal with Hinova Pharmaceuticals Inc.
Evommune announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals for EVO570, an oral VAV1-directed molecular glue degrader. Evommune acquired worldwide rights (excluding Greater China) to develop, manufacture, and commercialize the candidate, which it plans to develop for rheumatoid arthritis.
Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M
Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral small-molecule calpain inhibitor for ophthalmic diseases, in all territories outside of Asia. Kiora will pay an upfront fee of $3.5 million, low teen millions upon technology transfer, and up to $168.5 million in potential regulatory and commercial milestones, plus single-digit royalties.
Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M
Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.
Zymeworks entered into a global collaboration and license agreement with Roche for the development and commercialization of ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive a $55 million upfront payment and a $40 million milestone upon Phase 1b trial initiation, with eligibility for up to $718 million in additional milestones plus tiered royalties.